Article info

Download PDFPDF

Tenascin-C, a novel target to inhibit new bone formation in axial spondyloarthritis, linked with inflammation, mechanical strain and tissue damage
Free

Authors

  1. Correspondence to Dr Rik Lories, Rheumatology, University Hospitals Leuven, Leuven, Belgium; rik.lories{at}kuleuven.be
View Full Text

Citation

Van Mechelen M, Lories R
Tenascin-C, a novel target to inhibit new bone formation in axial spondyloarthritis, linked with inflammation, mechanical strain and tissue damage

Publication history

  • Received May 4, 2021
  • Accepted May 6, 2021
  • First published May 14, 2021.
Online issue publication 
June 17, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.